Across TCGA pan-cancer cohorts, NUTM2G Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NUTM2G data layer compared with 23 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher NUTM2G Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NUTM2G expression acts as an unfavorable survival marker.

SCLC, UCEC, and LGG are the cancer types where NUTM2G Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	DFS	Median	All	0.201	0.728	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NUTM2G tumor-vs-normal RNA expression · all NUTM2G data types